Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed. Tambiciclib (SLS009), a highly selective CDK9 ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SELLAS Life Sciences Group, Inc. announced positive overall survival results from their ongoing Phase 2 trial of SLS009 (tambiciclib) in patients with relapsed/refractory acute myeloid leukemia (AML), ...
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) today provided a business update and will host a webinar at 9:00 am ET. “We believe that 2025 will be a pivotal year for SELLAS as we continue to advance ...
SILVER SPRING, Md., Aug. 3, 2017 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Vyxeos for the treatment of adults with two types of acute myeloid leukemia (AML): ...
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results